EZH2 and Miyoshi myopathy: Treatment of MM cells with s-ASO-g11 and s-ASO-g12 reduced EZH2 activation, resulting in lowered H3K27me3 levels, which was found to be comparable to treatment using known EZH2 inhibitor (Tazemetostat) (Fig. 5g and Supplementary Fig. 6d).